<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To investigate the risk factors and clinical significance of blood-<z:chebi fb="23" ids="18059">lipid</z:chebi> <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorder</z:e> in schizophrenic patients caused by <z:chebi fb="1" ids="37931,37932">phenothiazine</z:chebi> treatment for long term (from 1 month to 25 years) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Serum levels of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> AI (apoAI), <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (apoB), <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>), <z:chebi fb="0" ids="17855">triglyceride</z:chebi> (TG), and total cholesterol (TC) were measured in 120 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0100753'>schizophrenia</z:hpo> patients, 50 vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, and 100 <z:mpath ids='MPATH_458'>normal</z:mpath> controls by the enzyme method and immune fluoroscopy turbidimetric method </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The patients with <z:hpo ids='HP_0100753'>schizophrenia</z:hpo> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> had significantly lower content of apoAI, <z:chebi fb="0" ids="47775">HDL-C</z:chebi>, and apoAI/apoB than those in <z:mpath ids='MPATH_458'>normal</z:mpath> control (P&lt;0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>Their apoB and TG levels were higher than the healthy control group (P&lt;0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>The TG contents in the negative group and the vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> group were obviously higher than the positive group (P&lt;0.01) while there was no marked difference between the TC levels in the three groups and the <z:mpath ids='MPATH_458'>normal</z:mpath> control group (P&gt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: The <z:hpo ids='HP_0011010'>chronic</z:hpo> schizophrenic patients have a blood-<z:chebi fb="23" ids="18059">lipid</z:chebi> <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorder</z:e> by long-term intake of <z:chebi fb="1" ids="37931,37932">phenothiazine</z:chebi> drugs </plain></SENT>
<SENT sid="6" pm="."><plain>It is suggested that the traditional treatment with antipsychotic should reformed, and that drugs of degrading <z:chebi fb="23" ids="18059">lipid</z:chebi> and coagulation should be used to prevent and reduce the risk factors causing the <z:hpo ids='HP_0003674'>onset</z:hpo> of cardiovascular and cerebrovascular diseases and delay the development of the disturbance of intelligence and <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>